About Authors:
Mubarak Patel*, Suresh. V. Kulkarni,
Department of Pharmaceutics,
Sree Siddaganga College of Pharmacy,
B. H. Road, Tumkur-572102, Karnataka, India.


The purpose of the research work was to prepare and evaluate the microspheres of metoclopramide hydrochloride as a model drug by solvent evaporation method with carbopol and HPMC polymers in various proportions. A total of six formulations were prepared i.e. F1, F2, F3, F4, F5 and F6. The microspheres were evaluated for micromeritic properties, particle size, % yield, Drug content and Drug release. The size or average diameter of prepared microspheres were recognized and characterized by scanning electron microscopic methods. Microspheres were found discrete, spherical and free flowing. They ranged in particle size from 45.6- 52.2 μm. Metoclopramide hydrochloride release from these microspheres was slowed, extended and depended on the type of polymer used. The formulation F2 and F5 showed consistent drug release for up to 12 h time period. Among all the formulations, F2 contains carbopol 934 and F5 containing HPMC showed the reproducible results with best release profile and good surface morphology. Release data were analyzed based on Highuchi kinetics and Korsmeyer/Peppa’s equation and all the selected formulations showed good fit to Peppa’s equation. The work has demonstrated that among all the formulations of microspheres, particularly those of formulation F2 are promising candidates for the sustained release of metoclopramide hydrochloride in the gastrointestinal tract.

Walk-in: Sales Executives Require at H&H Pharmaceuticals Pvt. Ltd.

Multicrore, Fast growing, all India Pharmaceutical company, leader in skin care requires Dermatological Sales Executives for various Head Quarters in East and North Eastern states like Bhubaneswar, Rourkela, Sambalpur, Balangir, Siliguri, Cooch Behar, Guwahati, Shillong, Bongaigaon, Tezpur, Lakhimpur, Silchar, Imphal, Dimapur, Jorthat, Dibrugarh etc.

Walk-in-interview in Glenmark for the Sales Positions | Mumbai, Bangalore, Delhi

Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.